Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session 2: GI, lower digestive

LBA24 - KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation

Date

12 Sep 2022

Session

Proffered Paper session 2: GI, lower digestive

Topics

Targeted Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Samuel Klempner

Citation

Annals of Oncology (2022) 33 (suppl_7): S808-S869. 10.1016/annonc/annonc1089

Authors

S.J. Klempner1, J. Weiss2, M. Pelster3, A. Spira4, M. Barve5, S.I. Ou6, T.A. Leal7, T. Bekaii-Saab8, J.G. Christensen9, T. Kheoh10, K. Velastegui11, H. Der Torossian11, R. Yaeger12

Author affiliations

  • 1 Department Of Medicine, Massachusetts General Cancer Center, 02114 - Boston/US
  • 2 Department Of Oncology, University of North Carolina-Chapel Hill, Lineberger Comprehensive Cancer Center, NC 27514 - Chapel Hill/US
  • 3 Gastrointestinal Research, Sarah Cannon Research Institute, 37203 - Nashville/US
  • 4 Research Institute, Virginia Cancer Specialists, 22031 - Fairfax/US
  • 5 Mary Crowley Cancer Research Center, Mary Crowley Cancer Research Center, 75201 - Dallas/US
  • 6 Division Of Hematology/oncology, University of California Irvine, Chao Family Comprehensive Cancer Center, 92868 - Orange/US
  • 7 Department Of Hematology And Medical Oncology, Winship Cancer Institute, Emory University, 30322 - Atlanta/US
  • 8 Department Of Medical Oncology And Hematology, Mayo Clinic Cancer Center, 85054 - Phoenix/US
  • 9 Chief Scientific Officer, Mirati Therapeutics, Inc., 92121 - San Diego/US
  • 10 Biometrics, Mirati Therapeutics, Inc., 92121 - San Diego/US
  • 11 Clinical Development, Mirati Therapeutics, Inc., 92121 - San Diego/US
  • 12 Department Of Medicine, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA24

Background

KRASG12C mutations occur in 3–4% of CRC and are associated with shorter PFS and OS with standard chemotherapy. Adagrasib (ada), a selective and irreversible KRASG12C inhibitor, is optimized for a long half-life (23 h), dose-dependent PK, and CNS penetration. Durable inhibition of KRASG12C may be important in CRC, due to signaling pathways creating susceptibility to feedback reactivation of RAS. Preclinical data suggest dual EGFR/KRASG12C blockade may enhance inhibition of KRAS-dependent signalling and overcome adaptive feedback.

Methods

KRYSTAL-1 (NCT03785249) is a multicohort Ph 1/2 study evaluating safety and efficacy of ada in patients (pts) with KRASG12C-mutated advanced solid tumors. Ada (600 mg BID) and ada + cetuximab (cetux; 400 mg/m2 followed by 250 mg/m2 QW or 500 mg/m2 Q2W) were evaluated in pts with previously treated CRC, in Ph 2 and 1b cohorts, respectively. Responses were investigator assessed.

Results

As of Jun 16 2022, 44 pts received ada and 32 pts received ada + cetux. In the ada mono cohort (median follow-up 20.1 mo), median age was 59 yrs, 50% were female, median prior lines of systemic therapy was 3, 52% and 48% were ECOG PS 0 and 1, respectively. In 43 pts evaluable for efficacy, ORR was 19% (8/43), and DCR was 86% (37/43). Median DOR was 4.3 mo (95% CI 2.3–8.3) and median PFS was 5.6 mo (95% CI 4.1–8.3). In the ada + cetux cohort (median follow-up 17.5 mo), median age was 60 yrs, 53% were female, median prior lines of systemic therapy was 3, 44% and 56% were ECOG PS 0 and 1, respectively. In 28 pts evaluable for efficacy, ORR was 46% (13/28) and DCR was 100% (28/28). Median DOR was 7.6 mo (95% CI 5.7–NE) and median PFS was 6.9 mo (95% CI 5.4–8.1). Gr 1–2 and 3–4 TRAEs occurred in 59% and 34% of pts, respectively, in the ada cohort, and 84% and 16% of pts, respectively, in the ada + cetux cohort. No Gr 5 TRAE occurred.

Conclusions

Adagrasib is well tolerated as monotherapy and with cetuximab. Both showed clinical activity in heavily pretreated pts with KRASG12C-mutated CRC, with more sustained responses with the combination. Adagrasib + cetuximab is being investigated in 2L CRC in the Phase 3 KRYSTAL-10 trial (NCT04793958).

Clinical trial identification

NCT03785249.

Editorial acknowledgement

Third-party medical writing support, under the direction of the authors, was provided by Victoria Eyre-Brook of Ashfield MedComms, an Inizio company, and was funded by Mirati Therapeutics, Inc.

Legal entity responsible for the study

Mirati Therapeutics, Inc.

Funding

Mirati Therapeutics, Inc.

Disclosure

S.J. Klempner: Financial Interests, Personal, Advisory Board, Stomach Cancer Advisory Board: Eli Lilly, Merck, Bristol Myers Squibb, Astellas, Daiichi Sankyo, Pieris; Financial Interests, Personal, Advisory Board, One Time Advisory Board: Natera; Financial Interests, Personal, Advisory Board, Stomach cancer advisory board x 1: Mersana, Sanofi-Aventis; Financial Interests, Personal, Stocks/Shares, Stock Ownership: Turning Point Therapeutics; Financial Interests, Personal, Stocks/Shares, Early investor, company is not public: MBrace; Financial Interests, Institutional, Invited Speaker, National PI for trial: Leap Therapeutics; Financial Interests, Personal and Institutional, Invited Speaker, Local PI for trial, also served on advisory board as noted above: Astellas; Financial Interests, Institutional, Invited Speaker: Macrogenics; Financial Interests, Institutional, Invited Speaker, Trial PI: Silverback; Non-Financial Interests, Advisory Role, Medical-Scientific Advisory Board Member: Debbies Dream Foundation; Non-Financial Interests, Advisory Role, Member of Scientific Advisory Board: Hope for Stomach Cancer; Non-Financial Interests, Other, Member of Gastric and Esophageal NCCN Guideline Committees: NCCN. J. Weiss: Financial Interests, Advisory Board: Genmab, AstraZeneca, EMD Serono, Genentech, Inivata, Celgene, G1 Therapeutics, Jounce Therapeutics, AbbVie, Rakuten Medical, Nanobiotix, Azitra, Lilly, Blueprint Medicines, Pfizer, Jazz Pharmaceuticals, Boehringer Ingelheim, Regeneron; Financial Interests, Stocks/Shares: Nektar, Vessalon. M. Pelster: Financial Interests, Institutional, Principal Investigator: Arcus Biosciences, Astellas, Codiak Biosciences, CytomX, Gritstone Oncology, HiberCell, Immune-Onc Therapeutics, Surface Oncology, SQZ Biotechnologies, ZielBio; Financial Interests, Institutional, Advisory Role: Bayer, Novartis, AstraZeneca. A. Spira: Financial Interests, Personal, Other, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Array Biopharma, Blueprint Medicines; Financial Interests, Personal, Other, Consulting or Advisory Role / Honoraria: Amgen, Novartis, Takeda, AstraZeneca/MedImmune, Merck, Bristol-Myers Squibb; Financial Interests, Personal, Other, Honoraria: CytomX Therapeutics, Janssen Oncology, Bayer; Financial Interests, Institutional, Officer, CEO: NEXT Oncology Virginia; Financial Interests, Personal, Stocks/Shares: Eli Lilly; Financial Interests, Institutional, Invited Speaker: LAM Therapeutics, Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Newlink Genetics, Incyte, AbbVie, Ignyta, Trovagene, Takeda, Macrogenics, CytomX Therapeutics, Astex Pharmaceuticals, Bristol-Myers Squibb, Loxo, Arch Therapeutics, Gritstone, Plexxikon, Amgen, Daiichi Sankyo, ADCT, Janssen Oncology, Mirati Therapeutics, Rubius, Synthekine, Mersana, Blueprint Medicines. M. Barve: Financial Interests, Stocks/Shares: Texas Oncology Physician Associates; Financial Interests, Funding: Mary Crowley Cancer Research. S.I. Ou: Financial Interests, Personal, Invited Speaker: Pfizer, Roche; Financial Interests, Personal, Advisory Board: JNJ/Janssen, Elevation Oncology; Financial Interests, Personal, Stocks/Shares: Turning Point Therapeutics, Elevation Oncology; Financial Interests, Institutional, Invited Speaker: Pfizer, Mirati, JNJ/jassen, Merus. T.A. Leal: Financial Interests, Advisory Board: Daiichi Sankyo, Beyond Spring Pharmaceuticals, BMS, Merck, Takeda, Genentech, Invision First Lung, AstraZeneca, Novocure, Jazz Pharmaceuticals, EMD Serono, Boehringer Ingelheim, Blueprint Medicines. T. Bekaii-Saab: Financial Interests, Advisory Board: Replimune Artiva, Imugene, Immuneering, Xilis, Sun Biopharma; Financial Interests, Research Grant: BMS, Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer; Financial Interests, Other, Data monitoring committees: Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck/Eisai, PanCan, 1Globe; Financial Interests, Other, Inventions/patents: WO/2018/183488: human PD-1peptide vaccines and uses thereof –Licensed to Imugene, WO/2019/055687: methods and compositions for the treatment of cancer cachexia –Licensed to Recursion; Financial Interests, Advisory Role: Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merck, Stemline, AbbVie, Boehringer Ingelheim, Janssen, Daichii Sankyo, Natera, TreosBio, Celularity, Exact Science, Sobi, Beigene, Kanaph, AstraZeneca, Deciphera, MJH Life Sciences, Aptitude Health, Illumina, Foundation Medicine. J.G. Christensen: Financial Interests, Advisory Board: Bridge Biosciences; Financial Interests, Officer: Mirati Therapeutics; Financial Interests, Full or part-time Employment: Mirati Therapeutics; Financial Interests, Stocks/Shares: Mirati Therapeutics. T. Kheoh: Financial Interests, Full or part-time Employment: Mirati Therapeutics; Financial Interests, Stocks/Shares: Mirati Therapeutics. K. Velastegui: Financial Interests, Full or part-time Employment: Mirati Therapeutics. H. Der Torossian: Financial Interests, Full or part-time Employment: Mirati Therapeutics; Financial Interests, Stocks/Shares: Mirati Therapeutics. R. Yaeger: Financial Interests, Advisory Board: Array Biopharma/ Pfizer, Mirati Therapeutics, Natera; Financial Interests, Research Grant: Array Biopharma/ Pfizer, Boehringer Ingelheim, Mirati Therapeutics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.